print_label | resize_label

When oral agents in addition to diet and exercise aren’t enough, consider adding BYDUREON—a once-weekly type 2 diabetes treatment option proven to provide powerful and sustained A1C reductions with the additional benefit of weight loss.*1,2

View DURATION-3 Study Design

Impact on A1C.

Clinical Data

Impact on A1C.

Designed to be patient-friendly.

BYDUREON Pen

Designed to be patient-friendly.

Multiple glycemic effects in the body.

GLP-1 RA Therapy

Multiple effects of GLP-1 in the body.

Get on-site training from a Clinical Educator.

SteadySTART™ Program

Get on-site training from a Clinical Educator.

X

DURATION-3: 3-year, randomized, open-label study with a core 26-week phase with a primary endpoint of change in A1C from baseline at 26 weeks, and a prespecified 130-week extension phase in which patients continued randomized treatment. The primary endpoint at 156 weeks was change in A1C from baseline. In this study, adult type 2 diabetes patients with suboptimal glycemic control (A1C 7.1%-11%) despite maximum tolerated doses of metformin alone or with a sulfonylurea were assigned to once-weekly BYDUREON 2 mg or once-daily insulin glargine (titrated based on INITIATE algorithm). Of the 456 randomized patients, 287 completed 3 years of treatment. Patient demographics (mITT): BYDUREON: 52% male, 82% Caucasian; FPG, 178.2 mg/dL; duration of diabetes, 8 years (mean); insulin glargine: 55% male, 85% Caucasian; FPG, 174.6 mg/dL; duration of diabetes, 7.8 years (mean).1 Patients in the insulin glargine arm were dosed based on the INITIATE algorithm.5 Concomitant oral glucose lowering therapies were continued at stable doses until at least week 48, after which changes could be made. The following changes were reported (n, [%]): increase in the dose of oral agent: BYDUREON, 47 (20%) and insulin glargine, 14 (6%); addition of insulin (or adding another insulin): BYDUREON, 4 (2%) and insulin glargine, 15 (7%); adding another oral agent: BYDUREON, 27 (12%) and insulin glargine, 16 (7%).1

CLOSE

When oral agents in addition to diet and exercise aren’t enough, consider adding BYDUREON—a once-weekly type 2 diabetes treatment option proven to provide powerful and sustained A1C reductions with the additional benefit of weight loss.*1,2

View DURATION-3 Study Design